{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A single-centre phase II study was conducted"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with colorectal peritoneal metastases undergoing CRS-HIPEC"
      },
      "Intervention": {
        "score": 2,
        "evidence": "SPECT/computed tomography (CT) was undertaken before surgery, after intravenous administration of 10\u2005mg 111 In-labelled DOTA\u2013labetuzumab-IRDye800CW"
      },
      "Objective": {
        "score": 1,
        "evidence": "The aim of this study was to validate these results."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "tumour-to-background ratios (TBRs) and peritoneal cancer index scores were analysed."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Seven patients were included."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The mean(standard deviation, s.d.) SPECT/CT peritoneal cancer index score was 3(2), and the intraoperative score was 14(7) ( P = 0.032)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No study-related severe adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}